BeiGene Ltd. (BGNE)

146.04
0.89 0.61
NASDAQ : Health Technology
Prev Close 145.15
Open 145.15
Day Low/High 143.50 / 147.53
52 Wk Low/High 105.19 / 182.31
Volume 201.78K
Avg Volume 249.80K
Exchange NASDAQ
Shares Outstanding 59.77M
Market Cap 8.47B
EPS -12.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BeiGene Reports Second Quarter 2019 Financial Results

BeiGene Reports Second Quarter 2019 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, Aug.

Priority Review Granted To BeiGene's Supplemental New Drug Application In China For Tislelizumab In Urothelial Carcinoma

Priority Review Granted To BeiGene's Supplemental New Drug Application In China For Tislelizumab In Urothelial Carcinoma

BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BKE, CEL, INOD, INTX, MDP Downgrades: ATTO, BPI, CPE, ENDP, NP Initiations: BGNE Read on to get TheStreet Quant Ratings' detailed report:

BeiGene And SpringWorks Therapeutics Enter Into Global Clinical Collaboration To Evaluate Targeted Combination Therapy In Advanced Solid Tumors

BeiGene And SpringWorks Therapeutics Enter Into Global Clinical Collaboration To Evaluate Targeted Combination Therapy In Advanced Solid Tumors

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a...

Celgene Says Juno, Impact Deals Won't Be Its Last

Celgene Says Juno, Impact Deals Won't Be Its Last

The biopharmaceutical giant's top executive says the company will continue to aggressively invest in R&D and deploy capital to acquire or license assets.

TheStreet Quant Rating: D (Sell)